Public Profile

Viatris

Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn, is headquartered in the United States. Established in 2020, Viatris operates in over 165 countries, focusing on the pharmaceutical industry with a commitment to providing access to high-quality medicines. The company’s core business areas include generic and specialty pharmaceuticals, biosimilars, and over-the-counter products. Viatris is renowned for its extensive portfolio, which features a diverse range of medications that address various health conditions, including chronic diseases and infectious diseases. Its unique approach combines a broad product offering with a strong emphasis on patient access and affordability. With a significant market presence, Viatris has achieved notable milestones, including the successful integration of its legacy companies and a commitment to sustainable healthcare solutions.

DitchCarbon Score

How does Viatris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

46

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Viatris's score of 46 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Viatris's reported carbon emissions

In 2023, Viatris reported total carbon emissions of approximately 4,105,000 kg CO2e for Scope 3 and 295,000 kg CO2e for Scope 2 emissions in the UK. Notably, Scope 1 emissions were recorded at zero. Globally, the company’s emissions included about 335,600,000 kg CO2e for Scope 1 and approximately 416,100,000 kg CO2e for Scope 2, resulting in a total of around 751,600,000 kg CO2e for both scopes. Viatris has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030 from a 2020 baseline. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions, which encompass purchased goods and services, capital goods, and upstream transportation and distribution, within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit warming to 1.5°C. Furthermore, Viatris has committed to achieving net zero emissions for its UK operations by 2050, reinforcing its dedication to sustainability and climate action.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201520162017201820192020202120222023
Scope 1
299,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
354,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
653,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000
-
0,000,000,000
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Viatris's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Viatris is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Viatris is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Adcock Ingram Holdings Limited

ZA
Pharmaceutical Preparation Manufacturing
Updated 20 days ago

Bausch Health Cos

CA
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Csl

AU
Health and social work services (85)
Updated 6 days ago

Sandoz

CH
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Reckitt

GB
Retail trade services, except of motor vehicles and motorcycles; repair services of personal and household goods (52)
Updated 7 days ago

Teva Pharmaceuticals

IL
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers